Indication-based pricing and a new approach to negotiating between companies to address issues arising from UK competition law will be key to ensuring that combination therapies reach patients, heard delegates at a 4 May online event, Confronting The Challenge Of Combination Treatments.
Though speakers at the event agreed that some drugs might end up with a lower price, they appealed to industry...